Compare Ascendis Pharma A/S (ASND) vs Johnson Controls International PLC (JCI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Johnson Controls International PLC — how do they compare? Ascendis Pharma A/S trades at $256 (market cap $16.67B), while Johnson Controls International PLC trades at $154.59 (market cap $93.74B). The key difference: Johnson Controls International PLC is far larger — about 5.6× Ascendis Pharma A/S's market cap, and Johnson Controls International PLC pays a 1.03% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | JCI | |
|---|---|---|
Market Cap | $16.67B | $93.74B |
Sector | Health | Industrials |
52-Week High | $277.18 | $154.76 |
52-Week Low | $189.74 | $103.52 |
Enterprise Value | $17.04B | $102.58B |
Dividend Yield | — | 1.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $255.17, down slightly by 0.18% on the day, while maintaining strong analyst support with 92% buy ratings and a $309.75 consensus price target. The company shows impressive revenue growth from $51M in 2022 to $720M in 2025, with profitability improving as net loss narrows to -$228M. Recent technical indicators show a bullish trend with the stock trading near resistance at $255-257, while fundamental metrics reveal high valuation ratios (P/E 29.05, P/S 15.68) offset by exceptional gross margins of 89.04%.
ASND presents a compelling growth story with multiple product launches in rare endocrine diseases driving revenue expansion, though investors face risks from negative shareholder equity and high debt levels. The company's transition to positive operating cash flow ($54M in 2025) and inclusion in Russell indexes signal maturation, but execution risks remain as the stock trades at premium valuations requiring continued strong performance to justify current levels.
Johnson Controls International (JCI) trades at $154.06, up 2.23% on the day, with a bullish technical signal from moving averages and strong recent earnings beats. The company reported robust Q3 2026 results with organic sales growth of 10% and raised its full-year guidance, driven by demand for data-center thermal management systems. Valuation ratios are elevated, with a P/E of 43.59 and P/S of 3.82, reflecting growth expectations. The stock is near its pivot point of $154, with immediate resistance at $155.
The outlook for JCI is positive, supported by strong operational momentum and strategic positioning in energy-efficient building solutions. Key opportunities include expanding AI-related cooling demand and consistent earnings outperformance. Risks involve high valuation multiples, increasing debt-to-asset ratios, and potential macroeconomic pressures on construction markets. Analyst consensus remains strongly bullish with a $168.25 price target, though investors should monitor execution on growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Johnson Controls International PLC
Johnson Controls manufactures, installs, and services HVAC systems, building management systems and controls, industrial refrigeration systems, and fire and security solutions. Commercial HVAC accounts for about 40% of sales, fire and security also represents 40% of sales, and residential HVAC, industrial refrigeration, and other solutions account for the remaining 20% of revenue. In fiscal 2021, Johnson Controls generated over $23.5 billion in revenue.
Read more on JCI →
